Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, will...
HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, and its academic collaborators in...
HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, today...
HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced an agreement with Biodesix, Inc....
HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced the acquisition of Biothera...
HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, today announced the appointment of...
HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, launched today with $60.75M in Series ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.